CDK7-IN-30 (Compound 22) is an inhibitor of CDK7 with an IC50 value of 7.21 nM, effectively inhibiting the phosphorylation of RNA polymerase II and CDK2. It can induce cell apoptosis (apoptosis) and exhibits anticancer activity, making it useful for cancer research.

CDK3:370.40 nM, CDK4:644.80 nM, CDK5:3678.50 nM, CDK9:704.3 nM, CDK1:>10000.00 nM, CDK6:1345.50 nM, CDK2:734.55 nM, CDK7:7.21 nM

CDK7-IN-30 (Compound 22) exhibits potent antiproliferative effects against cancer cells, with IC 50 values of 288.0 nM in RS4;11, 174.6 nM in MM.1S, 37.5 nM in Mino, and 168.7 nM in Jeko-1. In contrast, its inhibitory effect on normal blood cells (PBMCs) is weaker, with an IC 50 value of 757.9 nM. Additionally, CDK7-IN-30 (50-500 nM; 24 h) induces cell cycle arrest at the G1/S phase in MV4-11 cells and (100-1000 nM; 48 h) promotes apoptosis.